Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Other US Agencies Respond To The Pandemic, FEMA Fine-Tunes Plan Of Action

Executive Summary

Industry wonders how emergency agency's COVID-19 public-private partnerships will fit in with the others.

You may also be interested in...



DOJ OKs Supply Chain 'Control Tower' Collaboration Against COVID-19 Drug Shortages

AmerisourceBergen, McKesson, Cardinal and others can help FEMA deliver hydroxychloroquine and manage critical-drugs supply chain without running afoul of federal antitrust law.

Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need

Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.

How To Host Onsite Drug GMP Inspections Without Spreading The Coronavirus

US FDA suggests meeting with investigators onsite by video instead of in person, moving document rooms outside, avoiding paper and more. UK MHRA shares similar recommendations.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel